FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002230464> ?p ?o ?g. }

• W2002230464 endingPage "A507" @default.
• W2002230464 startingPage "A507" @default.
• W2002230464 abstract "The high sensitivity of the pentagastrin stimulation test in detecting primary or metastatic medullary thyroid cancer (MTC) suggests a widespread expression of the corresponding receptor type on human MTC. Indeed, autoradiographic studies demonstrated cholecystokinin (CCK)-B/gastrin receptors not only in more than 90% of MTCs, but also in a high percentage of small-cell lung cancers, stromal ovarian tumors, and potentially a variety of other tumors, including gastrointestinal adenocarcinomas, neuroendocrine tumore, and malignant glioma. The aim of our work was to develop and systematically optimize suitable radioligands for targeting CCK-B receptors in vivo and to investigate their role in the staging and therapy of MTC and other CCK-B receptor-expressing malignancies. For this purpose, a variety of CCK/gastrin-related peptides, all having in common the C-terminal CCK-receptor binding tetrapeptide sequence-Trp-Met-Asp-PheNH2 or derivatives thereof, were investigated. They were members of the gastrin or cholecystokinin famillies or possessed characteristics of both, which differ by the intramolecular position of a tyrosyl moiety. Their stability and affinity were studied and optimized in vitro and in vivo; their biodistribution and therapeutic efficacy were tested in preclinical models. Best tumor uptake and tumor to nontumor ratios were obtained with members of the gastrin family, because of their superior selectivity and affinity for the CCK-B receptor subtype. Radiometal-labeled derivates of minigastrin showed excellent targeting of CCK-B receptor-expressing tissues in animals and healthy human volunteers. Preclinical therapy experiments in MTC-bearing animals showed significant antitumor efficacy. In a subsequent clinical study, 45 MTC patients with metastatic MTC were investigated; 23 had known and 22 had occult disease. CCK-B receptor scintigraphy was performed with 111In-diethylenetriamine pentaacetic acid-d-Glu1-minigastrin. The normal organ uptake was essentially confined to the stomach (and, to a lesser extent, to the gallbladder and, in premenopausal women, to normal breast tissue) as a result of CCK-B receptor-specific binding and to the kidneys, as excretory organs. All tumor manifestations known from conventional imaging were visualized as early as 1 hour postinjection, with increasing tumor to background ratios over time; at least 1 lesion was detected in 20 of 22 patients with occult disease (patient-based sensitivity, 91%). Among them were local recurrences and lymph node, pulmonary, hepatic, splenic, and bone (marrow) metastases. Eight patients with advanced metastatic disease were injected in a dose-escalation study with potentially therapeutic activities of a 90Y-labeled minigastrin derivative at 4 to 6-week intervals (30–50 mCi/m2 per injection for a maximum of 4 injections). Hematologic and renal toxicities were identified as the dose-limiting toxicities at the 40 and 50 mCi/m2 levels. Two patients experienced partial remissions, and 4 experienced stabilization of their previously rapidly progressing disease. These data suggest that CCK-B receptor ligands may be a useful new class of receptor-binding peptides for diagnosis and therapy of a variety of (CCK-B receptor-expressing) tumor types. They allow for sensitive and reliable staging of patients with metastatic MTC. Initial therapeutic results are promising, but nephrotoxicity is a major concern to be solved." @default.
• W2002230464 created "2016-06-24" @default.
• W2002230464 creator A5029049777 @default.
• W2002230464 creator A5063983492 @default.
• W2002230464 creator A5066732458 @default.
• W2002230464 creator A5079971195 @default.
• W2002230464 date "2001-04-01" @default.
• W2002230464 modified "2023-10-14" @default.
• W2002230464 title "Both glycine-extended gastrin (G-gly) and gastrin (G17) stimulated COX-2 expression via CCK-B receptor in intestinal epithelial cells" @default.
• W2002230464 doi "https://doi.org/10.1016/s0016-5085(08)82517-6" @default.
• W2002230464 hasPublicationYear "2001" @default.
• W2002230464 type Work @default.
• W2002230464 sameAs 2002230464 @default.
• W2002230464 citedByCount "0" @default.
• W2002230464 crossrefType "journal-article" @default.
• W2002230464 hasAuthorship W2002230464A5029049777 @default.
• W2002230464 hasAuthorship W2002230464A5063983492 @default.
• W2002230464 hasAuthorship W2002230464A5066732458 @default.
• W2002230464 hasAuthorship W2002230464A5079971195 @default.
• W2002230464 hasConcept C107539642 @default.
• W2002230464 hasConcept C126322002 @default.
• W2002230464 hasConcept C134018914 @default.
• W2002230464 hasConcept C150903083 @default.
• W2002230464 hasConcept C170493617 @default.
• W2002230464 hasConcept C185592680 @default.
• W2002230464 hasConcept C207001950 @default.
• W2002230464 hasConcept C2776986829 @default.
• W2002230464 hasConcept C2777504413 @default.
• W2002230464 hasConcept C2777593968 @default.
• W2002230464 hasConcept C2779377912 @default.
• W2002230464 hasConcept C2779422922 @default.
• W2002230464 hasConcept C32110497 @default.
• W2002230464 hasConcept C49039625 @default.
• W2002230464 hasConcept C502942594 @default.
• W2002230464 hasConcept C71924100 @default.
• W2002230464 hasConcept C86803240 @default.
• W2002230464 hasConceptScore W2002230464C107539642 @default.
• W2002230464 hasConceptScore W2002230464C126322002 @default.
• W2002230464 hasConceptScore W2002230464C134018914 @default.
• W2002230464 hasConceptScore W2002230464C150903083 @default.
• W2002230464 hasConceptScore W2002230464C170493617 @default.
• W2002230464 hasConceptScore W2002230464C185592680 @default.
• W2002230464 hasConceptScore W2002230464C207001950 @default.
• W2002230464 hasConceptScore W2002230464C2776986829 @default.
• W2002230464 hasConceptScore W2002230464C2777504413 @default.
• W2002230464 hasConceptScore W2002230464C2777593968 @default.
• W2002230464 hasConceptScore W2002230464C2779377912 @default.
• W2002230464 hasConceptScore W2002230464C2779422922 @default.
• W2002230464 hasConceptScore W2002230464C32110497 @default.
• W2002230464 hasConceptScore W2002230464C49039625 @default.
• W2002230464 hasConceptScore W2002230464C502942594 @default.
• W2002230464 hasConceptScore W2002230464C71924100 @default.
• W2002230464 hasConceptScore W2002230464C86803240 @default.
• W2002230464 hasIssue "5" @default.
• W2002230464 hasLocation W20022304641 @default.
• W2002230464 hasOpenAccess W2002230464 @default.
• W2002230464 hasPrimaryLocation W20022304641 @default.
• W2002230464 hasRelatedWork W1020341931 @default.
• W2002230464 hasRelatedWork W1986625779 @default.
• W2002230464 hasRelatedWork W2008460537 @default.
• W2002230464 hasRelatedWork W2011129941 @default.
• W2002230464 hasRelatedWork W2031272904 @default.
• W2002230464 hasRelatedWork W2042058597 @default.
• W2002230464 hasRelatedWork W2042209138 @default.
• W2002230464 hasRelatedWork W2069633620 @default.
• W2002230464 hasRelatedWork W2083541482 @default.
• W2002230464 hasRelatedWork W2156781931 @default.
• W2002230464 hasVolume "120" @default.
• W2002230464 isParatext "false" @default.
• W2002230464 isRetracted "false" @default.
• W2002230464 magId "2002230464" @default.
• W2002230464 workType "article" @default.